Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentUnusual Whales·Aug 10 at 03:21 PMPALI-4.98%
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2benzinga_article·Jul 23 at 01:06 PMPALI-4.98%
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursdaybenzinga_article·Jul 23 at 06:29 AMPALI-4.98%SIG+1.44%
Palisade Bio, Inc. (NASDAQ:PALI) Given Average Recommendation of "Buy" by AnalystsMarket Beat·Jul 20 at 03:14 AMPALI-4.98%
Palisade Bio director Robert Baltera Jr acquires USD 88,687.50 in common sharesPUBT·Jul 10 at 05:15 PMPALI-4.98%
Palisade Bio to meet investors at Leerink Partners Therapeutics Forum July 14-15PUBT·Jul 10 at 08:00 AMPALI-4.98%
Palisade Bio director Robert Baltera Jr. acquires USD 101,044 of common sharesPUBT·Jul 8 at 05:56 PMPALI-4.98%
Palisade Bio director Robert Baltera Jr acquires USD 59,400 in common sharesPUBT·Jul 6 at 06:49 PMPALI-4.98%
